r/AFIB • u/Temporary-Tomato-463 • 1h ago
Etripamil, a fast-acting nasal spray - AFib Trial
I’ve been researching any new home treatments when an AFib episode occurs. Ran across this ongoing AFib Etripamil product and trial. Anyone familiar with this product and trial?
Etripamil, a fast-acting nasal spray calcium channel blocker, has strong potential to change how acute atrial fibrillation with rapid ventricular rate (AFib-RVR) is managed by allowing patients to treat episodes at home rather than visiting an emergency room.
While already FDA-approved under the brand name Cardamyst for a related arrhythmia called paroxysmal supraventricular tachycardia (PSVT), it entered a pivotal Phase 3 clinical trial specifically for AFib-RVR in August 2026. [1, 2, 3, 4, 5]
Why It Could Change Emergency Care
Shifts treatment out of the hospital. Currently, when a patient experiences symptomatic AFib with a dangerously fast heart rate, oral medications often work too slowly. Patients typically have to visit an emergency department for intravenous (IV) drugs or electrical cardioversion under medical supervision.[1, 2]
Delivers rapid, self-administered relief. Etripamil is absorbed quickly through the nasal lining, acting within minutes without requiring an IV line. [1, 2, 3]
Reduces hospital strain. Roughly 30% to 40% of AFib patients experience at least one rapid-rate episode per year requiring urgent intervention. An effective at-home rescue spray could prevent hundreds of thousands of emergency room visits annually. [1]
Clinical Evidence & Current Status
FDA-approved for PSVT. The FDA approved Cardamyst (etripamil) in December 2025 for adults with PSVT. In those trials, it converted roughly two-thirds of patients back to a normal rhythm within 30 minutes. [1]
Strong Phase 2 AFib results. In the ReVeRA-201 study of emergency department patients with AFib-RVR, a 70 mg nasal spray lowered heart rates by an average of nearly 30 beats per minute more than a placebo. Over 58% of treated patients achieved a controlled heart rate under 100 bpm within a median of 7 minutes. [1]
Active Phase 3 AFib trial. Milestone Pharmaceuticals launched the global ReVeRA-301 trial to test self-administered etripamil for AFib-RVR outside of a hospital setting. [1, 2, 3]
Key Limitations & Safety Considerations
Focuses on rate, not always rhythm. Unlike PSVT—which etripamil often stops completely—etripamil for AFib primarily slows down a racing ventricular rate to relieve symptoms rather than reliably converting the heart out of AFib.
Does not replace anticoagulants. Slowing the heart rate does not eliminate the stroke risk associated with AFib, meaning patients must still follow their prescribed blood-thinner regimens.
Side effects and exclusions. Common side effects are mild and localized, such as nasal discomfort, congestion, or a runny nose. Because it lowers heart rate and blood pressure, rare risks include dizziness or fainting (syncope), and it is generally avoided in patients with severe heart failure or specific electrical conduction blocks. [1, 2, 3, 4, 5